ACTION OF THYROID HORMONES IN SORAFENIB TREATMENT OF THYROID CANCER

CAMPOS HAEDO, M.N.; DIAZ ALBUJA, JOHANNA; CREMASCHI, GRACIELA A.; DÍAZ FLAQUÉ, M. CELESTE; PERONA, M; ROSEMBLIT, CINTHIA; STERLE, HELENA; JUVENAL, G

Congreso; REUNIÓN CONJUNTA SAIC SAI&FAIC SAFIS 2022; 2022

Background. Thyroid carcinoma (TC) is the most common endocrineneoplasia. Its incidence has increased in the last 40 years worldwide. Sorafenib (Sor), a tyrosine kinase inhibitor, was approved forthe treatment of TC, being hypothyroidism the most frequent consequence of Sor-induced endocrine dysfunction. We have describedthat thyroid hormones (TH) increase cell proliferation in TC lines.Thus, hormone replacement therapy to treat Sor-induced hypothyroidism could negatively affect the antitumor action. We have alsoshown that the selective inhibition of the TH membrane receptor,αVβ3 integrin, diminishes proliferation. Objective. To study integrinαVβ3 inhibition to enhance Sor antineoplastic activity in TC and themolecular mechanisms involved. Results. We first studied the roleof αvβ3 integrin in Sor inhibition of TH-induced proliferation in TCcells. The treatment of the human anaplastic 8505C TC cells withthe αvβ3 integrin antagonist Cilengitide (Cile) inhibits TH-inducedproliferation by MTS assay (p